USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SIBTECH, INC.
City: Brookfield
State: CT
Zip+4: 06804-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,300,119.00 23
SBIR Phase II $4,565,997.00 5

Award List:

TAGGED HUMAN TUMOR CELL LINES FOR METASTASIS RESEARCH

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $98,492.00

DIAGNOSTIC ASSAYS FOR TYPHOID--0 9,12 PORIN CONJUGATES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Aron, Lieselotte
Award Amount: $99,873.00

NEW METHODOLOGY FOR VEGF MEDIATED GENE DELIVERY

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Backer, Joseph M
Award Amount: $97,524.00

SITE SPECIFIC TRITIATION OF SYNTHETIC OLIGONUCLEOTIDES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sidorov, Victor
Award Amount: $98,050.00

TARGETING ANGIOGENESIS WITH TOXIN-VEGF FUSION PROTEINS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $99,296.00
Abstract:
Not Available Ground Moving Target Indicator (GMTI) radar is designed to suppress returns from stationary background (clutter) in order to detect and track moving objects which would otherwise be obscured. However, many applications of GMTI, such as the military applications of tracking and… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $369,685.00

TARGETING ANGIOGENESIS WITH TOXIN VEGF FUSION PROTEINS

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $0.00
Abstract:
DESCRIPTION: (Applicant's Description) The overall goal of this project is to develop a commercially viable bacterial toxin-VEGF (vascular endothelial growth… More

TARGETING ANGIOGENESIS WITH TOXIN VEGF FUSION PROTEINS

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $545,700.00
Abstract:
DESCRIPTION: (Applicant's Description) The overall goal of this project is to develop a commercially viable bacterial toxin-VEGF (vascular endothelial growth… More

VEGF-Based Delivery of Boron Therapeutics

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: DOE
Principal Investigator: Joseph M. Backer
Award Amount: $99,510.00
Abstract:
70733 Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to growing tumor blood vessels may form the basis for a highly selective anti-cancer therapy. Particularly… More

VEGF-Based Delivery of Boron Therapeutics

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: DOE
Principal Investigator: Joseph M. Backer
Award Amount: $0.00
Abstract:
70733S02-II Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to growing tumor blood vessels may form the basis for a highly selective cancer therapy. Particularly… More

Development of Monoclonal Antibody-Based Therapeutics for Treatment of Cancer

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Marina V. Backer, Senior Scientist
Award Amount: $69,367.00
Abstract:
Anti-cancer antibodies are potential molecular vehicles for targeted delivery of therapeutic and diagnostic agents to tumors and metastatic lesions. Currently,

VEGF-Based Delivery of Boron Therapeutics

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: DOE
Principal Investigator: Joseph M. Backer
Award Amount: $749,288.00
Abstract:
70733S02-II Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to growing tumor blood vessels may form the basis for a highly selective cancer therapy. Particularly… More

Targeted delivery of anti-anthrax therapeutics

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $107,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is the development of drug delivery vehicle that selectively targets cells affected by the anthrax toxin. The anticipated advantage of this system will be a decrease in side effects associated with systemic delivery of any… More

Pro-angiogenic Collagen Implants

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $183,750.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop a pro-angiogenic wound-healing implant. New tissue that replaces a wound should be vascularized through a process known as angiogenesis. Vascular endothelial growth factor (VEGF) is the major pro-angiogenic factor… More

VEGF-based targeted imaging of tumor vasculature

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $196,767.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop a highly sensitive system for cancer diagnostics based on targeted imaging of tumor neovasculature. Formation of new blood vessels through processes of angiogenesis and vasculogenesis is common, unique, and one of… More

Targeting anti-apoptotic drugs to failing cardiomyocytes

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $187,130.00
Abstract:
DESCRIPTION (provided by applicant): Heart failure is the major cause of morbidity and mortality worldwide. It is recognized that cardiomyocyte apoptosis plays an important role in heart failure. Intracellular proteases, known as caspases, play crucial rol e in initiation and execution of apoptosis.… More

Targeted Delivery of Anthrax Inhibitors

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Marina V. Backer
Award Amount: $213,510.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop a system for targeted delivery of anthrax toxin inhibitors. Antibiotic treatment currently approved as a post-exposure anthrax therapy is not effective against toxemia, whi ch is induced by anthrax toxins comprising… More

Development of Cu-64 Labeled EGF for In Vivo PET Imaging of EGFR Expression

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: DOE
Principal Investigator: Joseph M. Backer, Dr
Award Amount: $99,837.00
Abstract:
The DOE is seeking radiolabeled compounds that have applications as radiotracers for radionuclide imaging technologies, such as positron emission tomography and single photon emission computed tomography. In response, this project will develop 64Cu-labeled epidermal growth factor (EGF) as a… More

Molecular Targeted Imaging in Colon Cancer

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $162,918.00
Abstract:
DESCRIPTION (provided by applicant): There is an unmet need in a diagnostic procedure for colorectal cancer that relies on imaging of an early, specific, and well-understood molecular biomarker. We hypothesized that abnormally expressed receptors for vascu lar endothelial growth factor (VEGFR) are… More

VEGF-driven PET imaging of tumor angiogenesis

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $182,582.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is development of targeted PET probes for molecular imaging of receptors for vascular endothelial growth factor (VEGF), a crucial drug target in oncology patients. Tumor imaging with FDG , as well as imaging of tumor vasculature… More

VEGF-based Targeted Imaging of Tumor Vasculature

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $1,109,939.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop targeted probes for imaging receptors for vascular endothelial growth factor (VEGF) in tumor angiogenesis. Overexpressed VEGF receptors play the crucial role in the onset a nd progression of tumor angiogenesis and… More

Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Marina V. Backer
Award Amount: $245,842.00
Abstract:
DESCRIPTION (provided by applicant): Drug-resistant breast cancer cells are the main cause of recurrent disease. One mechanism of cancer cell survival and drug resistance is mobilization of GRP78/BiP, master-regulator of unfolded protein response and ER st ress. Because of its role, GRP78/BiP is… More

Targeted Molecular Radiotherapy for Rheumatoid Arthritis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: DOE
Principal Investigator: Joseph M. Backer, Dr.
Award Amount: $99,909.00
Abstract:
The progression of rheumatoid arthritis (RA), specifically, the growth of the bone-destroying pannus in RA joints, depends on the formation of new blood vessels, whose growth is mediated primarily by vascular endothelial growth factor (VEGF) and its cognate receptors. VEGF and its receptors are… More

Targeted delivery of Lu-177 to tumor vasculature

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer
Award Amount: $286,382.00
Abstract:
DESCRIPTION (provided by applicant): Our goal is to develop a targeted anti-cancer 177Lu radiotherapeutic agent that localizes to a tumor via receptor- mediated uptake by endothelial cells in the tumor vasculature. Due to beta emission (1.5 mm max dept h) 177Lu radiopharmaceutical is expected to… More

Targeted Delivery of Cardioprotective Drugs

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Marina V. Backer
Award Amount: $385,462.00
Abstract:
DESCRIPTION (provided by applicant): Myocardial infarction is a disabling disease, with infarct size being a major determinant of mortality. To limit infarct size and improve functional recovery, the ischemic myocardium has to be reperfused. However, reper fusion itself causes irreversible damage to… More

Targeted photoacoustic imaging of VEGF receptors in angiogenic vasculature

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph M. Backer – 203-775-5677
Award Amount: $286,918.00
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a contrast agent for photoacoustic imaging targeted to the receptors of vascular endothelial growth factor (VEGFR), so it can be accumulated and retained in tumor endothelial cells by VEGFR-mediated endocytosis. VEGFR are over expressed in… More

Targeted delivery of Lu-177 to tumor vasculature

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph M. Backer – 203-775-5677
Award Amount: $1,791,385.00
Abstract:
DESCRIPTION (provided by applicant): Currently available anti-angiogenic drugs inhibit VEGF/VEGFR signaling, which leads to transient vascular regression followed by rebound of drug-resistant vasculature, which significantly decrease the therapeutic efficacy of very expensive anti-angiogenic… More